Novo CEO scolds European officials for 'empty promises' on new drugs

Novo Nordisk ($NVO) CEO Lars Sørensen says Europe needs to loosen its purse strings to keep drug innovation coming. If austerity-minded governments aren't willing to pay for new drugs, then his company may have to choose not to launch new products there, choosing on a country-by-country basis where to do so. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.